|
Daniel Bradbury has been an Illumina Board of Director since January 2004. Currently Mr. Bradbury is President and Chief Executive Officer of Amylin Pharmaceuticals Inc. in San Diego CA. At Amylin he has served as President and Chief Operating Officer since June 2003 and a Director since June 2006. Prior to his promotion in June 2003 he was Executive Vice President since June 2000. He is a member of the board of directors of Novacea PhRMA BIOCOM the Keck Graduate Institute’s Board of Trustees and the San Diego Regional Economic Development Corporation. Mr. Bradbury is a member of the Royal Pharmaceutical Society of Great Britain and serves on the UCSD Rady School of Management’s Advisory Council.
Daniel obtained a bachelor of pharmacy degree from Nottingham University and a diploma in management studies from Harrow and Ealing Colleges of Higher Education. | 